Full article: Oral glucagon like peptide 1 receptor agonists and combinations of entero pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? Semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist, has well established weight loss benefits. Cagrilintide, a long acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination Targeting GLP 1, GIP & GCG in Obesity and Type 2 Diabetes Research The next frontier in metabolic health: Cagrilintide Semaglutide and the evolving landscape of therapies